What on-premise clinical AI evidence can support
On-premise deployment can support institutional control, while clinical authority requires evidence tied to the proposed action.
Super Genius Labs Editorial · Sep 18, 2026 · 3 min readReading the ADVOCATE awards through seven evidence states
A seven-state map helps operators distinguish ADVOCATE’s announced awards from authorization, deployment, and measured outcomes.
Super Genius Labs Editorial · Sep 16, 2026 · 3 min readThe FDA’s GenAI-device paper is a question set, not a compliance checklist
FDA is considering a competency-based evaluation model for generative-AI medical devices. Its discussion paper offers diligence questions about the finished device, intended use, clinical confirmation, and postmarket monitoring, not adopted requirements.
Super Genius Labs Editorial · Aug 23, 2026 · 4 min readWhat evidence should healthcare AI operators retain for non-device software?
FDA’s patient-safety inquiry gives healthcare AI operators a bounded prompt. Preserve intended use, observed benefits, safety signals, implementation lessons, governance practices, and evidence ownership without treating an operational record as a legal classification or proof of safety.
Super Genius Labs Editorial · Aug 13, 2026 · 4 min read